Treatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995)
- 1 December 1986
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 105 (6) , 856-861
- https://doi.org/10.7326/0003-4819-105-6-856
Abstract
Six patients with resistant acromegaly were given a long-acting somatostatin analogue (SMS 201-995) for 5 to 12 months. The clinical response was dramatic; relief of headache occurred within minutes of the injection. The mean 24-hour growth hormone levels fell acutely after the administration of 50 or 100 .mu.g every 12 hours, especially in four patients with small tumors (p < 0.001). Dosages of up to 1500 .mu.g/d were necessary to produce maximum lowering of growth hormone secretion in some patients. On long-term treatment, plasma somatomedin-C levels fell in all patients and became normal in four. Plasma immunoreactive levels of SMS 201-995 related inversely to growth hormone concentration: A reproducible threshold for growth hormone inhibition in five of the patients, ranging from 70 to 1200 pg/mL, was maintained for 6 to 8 hours after the injections. This somatostatin analogue is effective in the treatment of acromegaly, has no major side effects, and cause only transient changes in carbohydrate metabolism.Keywords
This publication has 11 references indexed in Scilit:
- Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic HormonesAnnals of Internal Medicine, 1985
- The Somatostatin Analog SMS 201-995 Induces Long-Acting Inhibition of Growth Hormone Secretion without Rebound Hypersecretion in Acromegalic Patients*Journal of Clinical Endocrinology & Metabolism, 1985
- Transsphenoidal surgery for acromegaly—long-term results in 100 patientsSurgical Neurology, 1985
- High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic PatientsJournal of Clinical Endocrinology & Metabolism, 1984
- Dopaminergic Treatment of Acromegaly: Different Effects on Hormone Secretion and Tumor Size *Journal of Clinical Endocrinology & Metabolism, 1984
- Somatostatin Sensitivity and Growth Hormone Responses to Releasing Hormones and Bromocryptine in AcromegalyJournal of Clinical Endocrinology & Metabolism, 1982
- No Effect of Bromocriptine in AcromegalyNew England Journal of Medicine, 1981
- Evaluation of Acromegaly by Radioimmunoassay of Somatomedin-CNew England Journal of Medicine, 1979
- The Insulin Resistance of Acromegaly: Evidence for Two Alterations in the Insulin Receptor on Circulating MonocytesJournal of Clinical Endocrinology & Metabolism, 1979
- INFLUENCE OF SOMATOSTATIN ON CARBOHYDRATE DISPOSAL AND ABSORPTION IN DIABETES MELLITUSThe Lancet, 1976